Global BiSpecific MAbS Market Growth (Status and Outlook) 2023-2029

Global BiSpecific MAbS Market Growth (Status and Outlook) 2023-2029

The global BiSpecific MAbS market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for BiSpecific MAbS is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for BiSpecific MAbS is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for BiSpecific MAbS is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key BiSpecific MAbS players cover Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Bristol Myers Squibb and Abbott, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “BiSpecific MAbS Industry Forecast” looks at past sales and reviews total world BiSpecific MAbS sales in 2022, providing a comprehensive analysis by region and market sector of projected BiSpecific MAbS sales for 2023 through 2029. With BiSpecific MAbS sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world BiSpecific MAbS industry.

This Insight Report provides a comprehensive analysis of the global BiSpecific MAbS landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on BiSpecific MAbS portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global BiSpecific MAbS market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for BiSpecific MAbS and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global BiSpecific MAbS.

This report presents a comprehensive overview, market shares, and growth opportunities of BiSpecific MAbS market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Catumaxomab (Removab™)
Blinatumomab
Emicizumab
Amivantamab
Others

Segmentation by application
Hospital
Research Institute
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
Novartis AG
Hoffmann-La Roche Ltd.
Novo Nordisk A/S
Bayer AG
Thermo Fisher Scientific
Bristol Myers Squibb
Abbott

Please note: The report will take approximately 2 business days to prepare and deliver.